This site is intended for healthcare professionals

Skyrizi phase III results demonstrate improvements in disease activity across joint and skin symptoms among psoriatic arthritis patients.- AbbVie

Read time: 1 mins
Last updated:6th Jan 2021
Published:6th Jan 2021
Condition: Psoriatic Arthritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest